Last reviewed · How we verify
NCT04512846
Comparison of Efficacy in SBRT of Large HCC With or Without TACE
trial in Large HCC Patients in 100 participants. Currently enrolling.
1 August 2023
Quick facts
| Lead sponsor | Beijing 302 Hospital |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 1 August 2020 |
| Primary completion | 1 August 2023 |
| Estimated completion | 30 August 2026 |
| Sites | 1 location across China |
Conditions studied
- Large HCC Patients — all drugs for Large HCC Patients →
- Stereotactic Body Radiation Therapy — all drugs for Stereotactic Body Radiation Therapy →
- Transcatheter Arterial Chemoembolization — all drugs for Transcatheter Arterial Chemoembolization →
Sponsor
Beijing 302 Hospital
Who can join
Adults 30 to 80, any sex, with Large HCC Patients or Stereotactic Body Radiation Therapy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study aims to compare efficacy and adverse reactions of large hepatocellular carcinoma participants (5-10cm) who receive stereotactic body radiation therapy with or without transcatheter arterial chemoembolization.The investigators will optimize the combined treatment schedule of SBRT for hepatocellular carcinoma participants by comparing overall survival rates, progression-free survival rates and local control and adverse reaction occurrence rates in the two groups.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04512846
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Beijing 302 Hospital trials
Trials by the same sponsor.
- NCT07514832 — VA-CIG Regimen for Previously Untreated Acute Myeloid Leukemia: A Multicenter Prospective Single-Arm Trial · Phase 2 · recruiting
- NCT07297173 — Phase 1 Study of Chemotherapy Plus HLA-mismatched GPBMC Infusion Bridging to Allo-HSCT for R/R Leukemia · Phase 1 · recruiting
- NCT06556862 — Exploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor · Phase 2 · not yet recruiting
- NCT07106658 — TEAS for Variceal Bleeding Endoscopy in Cirrhosis · NA · completed
- NCT06926647 — A Real-World Study of Antiviral Therapy in Children With Chronic Hepatitis B · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04512846 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beijing 302 Hospital
- Last refreshed: 27 June 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04512846.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing